Dr. Chantal Guillemette holds a Canada Research Chair in pharmacogenomics. She is a Professor at the Faculty of Pharmacy at Laval University and co-director of the Cancer Research Center (CRC) at Laval University.

Dr. Guillemette is one of the leaders in the field of the pharmacogenomics of phase II enzymes, with a focus on glucuronidation by UDP-glucuronosyltransferase enzymes (UGTs). Her international leadership comes from ground breaking discoveries in precision oncology that positioned her lab at the forefront of the global research on the most important pathway for the human body’s elimination of frequently prescribed drugs, also regulating hormonal drivers of cancer. Dr. Guillemette, along with her coworkers and external collaborators, have significantly advanced several areas of drug metabolism and cancer biomarkers. She has published over 130 papers, the majority as a senior author and her students as first authors. She also offers a productive, creative and dynamic training environment (>125 high qualified personnel) supported by a strong record of trainees (>60) and future scientists while educating undergrads and health professionals in pharmacology and personalized medicine. Her work has improved our understanding of the mechanisms contributing to variations in biotransformation by UGTs, and how this affects drug response and disease. This led to knowledge translation strategies for the clinical use of genetic information on drug metabolism by UGTs. Her work has also extended to the discovery of cancer predisposing genes and more recently, to the discovery of new prognostic markers uncovered for hormone-related cancers such as prostate cancer.

Her focus is now on two objectives well integrated with clinical unmet needs in high-incidence cancers (leukemia, prostate and lung) to address the mechanisms underlying variability in anticancer drugs and steroid metabolism and how this affects patients’ responses, disease progression and patients’ survival. A first objective comprehensively investigates the molecular mechanisms that underlie variability in anticancer drugs and steroid metabolism by UGTs using complementary models that integrate research on genomics, splicing and post-translational processes using cutting-edge technologies. These findings will greatly contribute to achieve the required mechanism-based evidence to propel progress in the field and their potential clinical applications, with an impact on a larger set of prescribed drugs and broad clinical settings. A second objective aims to establish, through translational studies of patients diagnosed with high-incidence cancers, the clinical implications of variability in steroid and anticancer drug metabolism pathways. Genetic, hormonal and pharmacological markers will be tested as part of predictive tools that can identify individuals more likely to suffer adverse reactions to novel anticancer substrates of UGTs and those who are more likely to respond to therapy. We also address how variability in steroid and drug metabolism pathways can help improve prognostic signatures for recurrence and cancer patient’s survival after initial treatment. This research is reinforced by a strong and efficiently balanced collaborative network of scientists supported by the active roles of clinicians. This research has the potential to improve personalization of oncology treatment and prognostication for frequent cancers.

CHUL
2705, boulevard Laurier
R-4701.5
Québec, Québec
Canada G1V 4G2
CHUL
2705, boulevard Laurier
R-4720
Québec, Québec
Canada G1V 4G2
157 entries « 1 of 16 »

Kourbanhoussen K, Joncas FH, D Wallis CJ, Hovington H, Dagenais F, Fradet Y, Guillemette C, Lacombe L, Toren P

Follicle-stimulating hormone (FSH) levels prior to prostatectomy are not related to long-term oncologic or cardiovascular outcomes for men with prostate cancer.

Journal Article

Asian J Androl, 2021.

Abstract | Links:

Leal YA, Song M, Zabaleta J, Medina-Escobedo G, Caron P, Lopez-Colombo A, Guillemette C, Camargo MC

Circulating Levels of Sex Steroid Hormones and Gastric Cancer.

Journal Article

Arch Med Res, 52 (6), 2021.

Abstract | Links:

De Mattia E, Polesel J, Roncato R, Labriet A, Bignucolo A, Gagno S, Buonadonna A, D'Andrea M, Levesque E, Jonker D, Couture F, Guillemette C, Cecchin E, Toffoli G

IL15RA and SMAD3 Genetic Variants Predict Overall Survival in Metastatic Colorectal Cancer Patients Treated with FOLFIRI Therapy: A New Paradigm.

Journal Article

Cancers (Basel), 13 (7), 2021.

Abstract | Links:

Poluri RT, Paquette V, Allain EP, Lafront C, Joly-Beauparlant C, Weidmann C, Droit A, Guillemette C, Pelletier M, Audet-Walsh E

KLF5 and NFYA factors as novel regulators of prostate cancer cell metabolism.

Journal Article

Endocr Relat Cancer, 28 (4), 2021.

Abstract | Links:

Kornauth C, Herbaux C, Boidol B, Guillemette C, Caron P, Mayerhöfer ME, Poulain S, Tournilhac O, Pemovska T, Chong SJF, Van der Kouwe E, Kazianka L, Hopfinger G, Heintel D, Jäger R, Raderer M, Jäger U, Simonitsch-Klupp I, Sperr WR, Kubicek S, Davids MS, Staber PB

Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia.

Journal Article

Haematologica, 106 (8), 2021.

| Links:

Caron P, Turcotte V, Guillemette C

A quantitative analysis of total and free 11-oxygenated androgens and its application to human serum and plasma specimens using liquid-chromatography tandem mass spectrometry.

Journal Article

J Chromatogr A, 1650 , 2021.

Abstract | Links:

Emond JP, Lacombe L, Caron P, Turcotte V, Simonyan D, Aprikian A, Saad F, Carmel M, Chevalier S, Guillemette C, Levesque E

Urinary oestrogen steroidome as an indicator of the risk of localised prostate cancer progression.

Journal Article

Br J Cancer, 125 (1), 2021.

Abstract | Links:

Carignan D, Lessard T, Villeneuve L, Desjardins S, Magnan S, Després P, Martin AG, Foster W, Guillemette C, Lévesque É, Vigneault E

DNA repair gene polymorphisms, tumor control, and treatment toxicity in prostate cancer patients treated with permanent implant prostate brachytherapy.

Journal Article

Prostate, 80 (8), 2020.

Abstract | Links:

Pouliot F, Rouleau M, Neveu B, Toren P, Morin F, Velot L, Ding K, Caron P, Lacombe L, Levesque E, Klotz L, Guillemette C

Extragonadal Steroids Contribute Significantly to Androgen Receptor Activity and Development of Castration Resistance in Recurrent Prostate Cancer after Primary Therapy.

Journal Article

J Urol, 203 (5), 2020.

Abstract | Links:

Petrick JL, Florio AA, Zhang X, Zeleniuch-Jacquotte A, Wactawski-Wende J, Van Den Eeden SK, Stanczyk FZ, Simon TG, Sinha R, Sesso HD, Schairer C, Rosenberg L, Rohan TE, Purdue MP, Palmer JR, Linet MS, Liao LM, Lee IM, Koshiol J, Kitahara CM, Kirsh VA, Hofmann JN, Guillemette C, Graubard BI, Giovannucci E, Gaziano JM, Gapster SM, Freedman ND, Engel LS, Chong DQ, Chen Y, Chan AT, Caron P, Buring JE, Bradwin G, Beane Freeman LE, Campbell PT, McGlynn KA

Associations Between Prediagnostic Concentrations of Circulating Sex Steroid Hormones and Liver Cancer Among Postmenopausal Women.

Journal Article

Hepatology, 72 (2), 2020.

Abstract | Links:

157 entries « 1 of 16 »
Signaler des ajouts ou des modifications

En tant que titulaire de la Chaire de recherche du Canada en pharmacogénomique, Chantal Guillemette poursuit trois principaux objectifs à long terme. Tout d’abord, elle tente de déterminer les marqueurs génétiques qui permettent de maximiser la réponse aux médicaments tout en limitant les effets secondaires associés à certaines pharmacothérapies du cancer. Elle analyse ensuite les caractéristiques des tumeurs, ce qui lui permet de définir les processus moléculaires liés à la réponse ou à la résistance au traitement.

En second lieu, la chercheure entend identifier des biomarqueurs génétiques ou biochimiques qui permettraient de déceler rapidement le cancer et les patients qui sont les plus susceptibles d’en être atteints. Enfin, l’objectif de Mme Guillemette vise à favoriser une meilleure compréhension des fonctions et des effets des variations génomiques, ce qui pourrait permettre d’intégrer la pharmacogénomique dans les études cliniques et permettre un transfert de connaissances plus rapide en clinique afin de maximiser et de personnaliser la pharmacothérapie.

Active projects

  • Chaire de recherche du Canada en pharmacogénomique, from 2020-10-01 to 2027-09-30
  • Effect of environmental contaminants and methylome of breast adipose tissue on aromatase inhibitor efficacy in breast cancer, from 2016-07-01 to 2024-09-30
  • Functional pharmacogenomics of cancer : from mechanisms to personalized therapy, from 2019-07-01 to 2026-06-30
  • Identifying selective glucuronidation inhibitors to overcome drug resistance in cancer, from 2020-06-01 to 2022-05-31
  • Interaction between environment, diet, physical activities, and sexual habits, in the risk of prostate cancer. Validation of biomarkers to personnalize preventive interventions., from 2012-10-01 to 2021-12-31
  • Recherche portant sur les hormones stéroïdiennes et sur le cancer de la prostate cliniquement localisé, from 2021-05-31 to 2022-03-31
  • The Contribution of Non-Classical 11-oxy Androgens to Prostate Cancer Progression, from 2019-04-01 to 2022-03-30
  • Une infrastructure IA multi-usagers clé en main pour gérer le cycle de vie complet des données en santé, from 2021-04-01 to 2021-11-30

Recently finished projects

  • Chaire de recherche du Canada en pharmacogénomique, from 2013-10-01 to 2020-09-30
  • Chaire Famille-Louis-Boivin, from 1997-04-01 to 2020-03-31
  • Évaluation d'une nouvelle classe de stéroïdes comme marqueurs pronostics et prédictifs, from 2020-12-16 to 2021-03-31
  • Reprogrammation métabolique en cancer : Rôle des enzymes UGT, from 2020-08-31 to 2021-03-31
  • Rôle de la protéine UGT2B17 dans l’agressivité et le processus de signalisation cellulaire de la leucémie lymphoïde chronique, from 2020-06-08 to 2021-08-31
  • UDP-glucose as a urine biomarker to predict the onset of acute kidney injury (AKI) in pediatric cardiac surgery patients, from 2021-05-15 to 2021-07-31
Data provided by the Université Laval research projects registery